Improving on Nature's Selection

Our novel antibody engineering platform, ATTOBODY™, consists of a proprietary design framework and an efficient discovery process that yields optimized bi-paratopic nanobodies consisting of two variable domains of single heavy chain (VHH) antibodies.

Enhanced efficacy and target selectivity

Bi-paratropic binding and binder optimization drive high affinity and specificity


Tunable half-life allows for flexibility in optimizing PK/PD to achieve ideal therapeutic index

success rates

Expanded epitope diversity and a greater number of druggable leads ​

development times

Simpler manufacturing shortens development times

Detecting Novel Biomarkers

The ATTOBODY platform enables the development of highly specific and sensitive detection reagents for challenging targets that lack quality off-the-shelf antibodies.  Combining ATTOBODY reagents with the NULISA assay platform will enable a new generation of precision diagnostics for the early detection of cancer and other common diseases.

To high affinity and beyond for biotherapeutics

A recent advertorial in Nature on our ATTOBODY technology.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. 

Learn more

Connect with us

Looking for more information? Contact us today and a representative will reach out to you soon.